Harout Semerjian

Harout Semerjian is a highly experienced professional with a diverse background in the pharmaceutical and healthcare industry.

He holds an MBA in General Management from Cornell Johnson Graduate School of Management, another MBA in General Management from Queen's University, and a Bachelor of Science in Biology from Lebanese American University.

Currently, he serves as the President and CEO at GlycoMimetics, showcasing his leadership skills and strategic vision.

Prior to this role, Harout Semerjian worked as an Independent Healthcare Consultant at Emerge Bio Consulting LLC, demonstrating his expertise in the healthcare consulting sector.

He has also held significant executive positions in renowned organizations such as Immunomedics, Ipsen, and Novartis Oncology.

At Ipsen, he excelled as the President, Head of Specialty Care International Region & Global Franchises, as well as the EVP & Chief Commercial Officer, highlighting his ability to drive commercial success and lead international teams effectively.

During his tenure at Novartis Oncology, Harout Semerjian held various leadership roles including Senior Vice President and Global Launch Lead, Vice President and Hematology Business Franchise Head, and VP & Region Head Oncology for the Middle East Cluster.

His experience at Novartis also includes roles such as General Manager for the Oncology Nordic Cluster, Business Unit Head Oncology for Denmark, and Director of Global Product Strategy for Glivec in Hematology.

Harout Semerjian began his career at Novartis Pharma Canada, where he served as the Associate Sales Director for Central Canada and later as the Brand Manager for Oncology.

In addition to his impressive corporate roles, Harout Semerjian's educational background in both business and biology equips him with a unique blend of skills and knowledge to navigate the complex landscape of the pharmaceutical industry.

With a track record of successful leadership and strategic decision-making, Harout Semerjian continues to make significant contributions to the healthcare and pharmaceutical sectors.